

Financial Tear Sheet

Company Profile

Merus discovers and develops differentiated therapeutics aimed at substantially prolonging the lives of cancer patients. It is our strategy to use the power of bispecific antibody engineering and advanced screening technologies to develop biopharmaceuticals that engage the power of the immune system to kill tumor cells.

Share Performance

MRUS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$16.79
Change (%)	▼ 0.31 (1.81%)
Volume	10,393
52 Week Low	\$14.05
Market Cap	\$387,020,880
Rolling EPS	-2.48
PE Ratio	0
Shares Outstanding	22,632,800
Data as of 10/19/18 12:59 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

News & Events

Date	Title
09/27/18	Merus to Present at the Cantor Fitzgerald Global Healthcare Conference

There are currently no events scheduled.

09/27/18 Merus Strengthens Team with Key Appointments

08/30/18 Merus to Participate in Citi's 13th Annual Biotech Conference

SEC Filings

Filing Date	Form
08/10/18	6-K
07/27/18	SC 13D/A
07/27/18	6-K
07/26/18	6-K

Supervisory Board

Ton Logtenberg, Ph.D	CEO, Executive Director
Russell Greig	Chairman, Non-Executive Director
Anand Mehra, M.D.	Non-Executive Director
John de Koning, Ph.D.	Non-Executive Director
Gregory Perry	Non-Executive Director
Mark Iwicki	Non- Executive Director
Len Kanavy	Non-Executive Director

Primary IR Contact

Kimberly Minarovich
Argot Partners
Phone: 1 212-600-1902
E-mail: kimberly@argotpartners.com

Management Board

Ton Logtenberg, Ph.D	CEO
Shelley Margetson	CFO